漳州片仔癀药业股份有限公司董事、监事和高级管理人员 漳州片仔癀药业股份有限公司 董事、监事和高级管理人员 2024 年 4 月 18 日 1、 公司严格按照股份制公司的财务制度规范运作，公司 2024 年第 一季度报告的编制符合法律、行政法规、《漳州片仔癀药业股 份有限公司章程》及公司内部管理制度的各项规定，《公司 2024 年第一季度报告》公允、真实、全面地反映了公司 2024 年第一 季度的财务状况和经营成果。 2、 公司第七届董事会第十八次会议、第七届监事会第十三次会议 审议通过《公司 2024 年第一季度报告》的议案。 3、 公司全体董事、监事和高级管理人员保证《公司 2024 年第一季 度报告》所披露的信息真实、准确、完整，承诺其中不存在任 何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、 准确性和完整性承担法律责任。 关于公司 2024 年第一季度报告的确认意见 根据《中华人民共和国证券法（2019 年修订）》《上海证券交易所股 票上市规则（2023 年修订）》和《上海证券交易所上市公司自律监管指南 第 1 号——公告格式（2023 年修订）》等相关法律法规，作为漳州片仔癀 药业股份有限公 ...

漳 州 片 仔 癀 药 业 股 份 有 限 公 司 章 程 （待二〇二三年年度股东大会审核） 福建·漳州 二〇二四年四月 1 / 46 目 录 | 第一章 | 总则 | | --- | --- | | 第二章 | 经营宗旨和范围 | | 第三章 | 股份 | | 第一节 | 股份发行 | | 第二节 | 股份增减和回购 | | 第三节 | 股份转让 | | 第四章 | 公司党组织 | | 第五章 | 股东和股东大会 | | 第一节 | 股东 | | 第二节 | 股东大会的一般规定 | | 第三节 | 股东大会的召集 | | 第四节 | 股东大会提案与通知 | | 第五节 | 股东大会的召开 | | 第六节 | 股东大会的表决和决议 | | 第六章 | 董事会 | | 第一节 | 董事 | | 第二节 | 董事会 | | 第三节 | 独立董事 | | 第七章 | 总经理及其他高级管理人员 | | 第八章 | 监事会 | | 第一节 | 监事 | | 第二节 | 监事会 | | 第九章 | 公司董事､监事､高级管理人员廉洁从业行为规范 | | 第十章 | 财务､会计和审计 | | 第一节 | 财务会计制度 | | ...

漳州片仔癀药业股份有限公司 2023 年度独立董事述职报告（陈蕾） 本人作为漳州片仔癀药业股份有限公司（以下简称"公 司"）第七届董事会独立董事，在 2023 年度本人任职期间严 格遵照《中华人民共和国公司法》《中华人民共和国证券法》 《中国证监会上市公司治理准则》《中国证监会上市公司独 立董事规则》等法律法规，以及《漳州片仔癀药业股份有限 公司章程》（以下简称"《公司章程》"）、《漳州片仔癀药业股 份有限公司独立董事工作制度》等规范性要求，谨遵忠实、 勤勉的原则，恪守独立董事履职规范，谨慎、独立、客观地 行使独立董事权利及义务。现将本人 2023 年度任职期间履 职情况报告如下： 一、独立董事的基本情况 作为公司独立董事，本人拥有较丰富的金融专业知识和 经验，并持有经济学博士学位和金融学教授职称，在从事的 专业领域积累了丰富的经验。本人个人工作履历、专业背景 以及任职情况如下： 陈蕾，女，1981 年 1 月出生，中共党员，博士研究生学 历，金融学专业。2006 年 7 月至 2006 年 12 月，任中国银行 福建省分行的国际结算部职员；2006年12月至2015年3月， 任集美大学的财经学院金融系教师； ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 漳州片仔癀药业股份有限公司（以下简称"公司"）根据《上市 公司独立董事管理办法（2023 年 8 月修订）》《上海证券交易所上市 公司自律监管指引第 1 号——规范运作（2023 年 12 月修订）》《上 市公司章程指引（2023 年 12 月修订）》《上市公司监管指引第 3 号 ——上市公司现金分红（2023 年 12 月修订）》等相关法律法规的要 求，为进一步完善公司治理，结合公司发展实际，公司拟对《漳州 片仔癀药业股份有限公司章程》（以下简称"《公司章程》"）部分条 款进行修订，详见修订前后对比表。 证券代码：600436 证券简称：片仔癀 公告编号：2024-019 漳州片仔癀药业股份有限公司 关于修订《公司章程》的公告 此次修改的《公司章程》于 2024 年 4 月 18 日经第七届董事会 第十八次会议审议通过。该议案尚需提交至公司股东大会审议。 同时，董事会提请股东大会授权公司管理层办理工商变更登记 等相关事宜。上述变更内容以工商登记机关最终核准内容为准。 特此公告。 ...

漳州片仔癀药业股份有限公司董事会 关于会计政策变更的说明 漳州片仔癀药业股份有限公司（以下简称"公司"）董事会就会 计政策、会计估计变更及重大会计差错更正事项说明如下： 一、会计政策变更 财政部于 2023 年 10 月 25 日发布《企业会计准则解释第 17 号》 （财会〔2023〕21 号）（以下简称"解释第 17 号"），公司根据修订 后的会计准则对相关会计政策进行变更。 2024 年 4 月 18 日，公司第七届董事会第十八次会议和第七届监 事会第十三次会议审议通过《公司关于会计政策变更的议案》。该议 案无需提交公司股东大会审议。 （一）会计政策变更的主要内容 财政部于 2023 年 10 月 25 日发布了《企业会计准则解释第 17 号》 （财会〔2023〕21 号，以下简称"解释第 17 号"）。《解释第 17 号》 规定，"关于流动负债与非流动负债的划分"、"关于供应商融资安排 的披露"和"关于售后租回交易的会计处理"内容自 2024 年 1 月 1 日起施行。 （二）变更日期 公司将根据财政部相关文件规定的起始日开始执行。 （三）变更前公司采用的会计政策 1 / 2 公司相关会计处理按照财政部 ...

证券代码：600436 证券简称：片仔癀 公告编号：2024-020 漳州片仔癀药业股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年年度股东大会 1 股东大会召开日期：2024年5月20日 本次股东大会采用的网络投票系统：上海证券交易所股东大 会网络投票系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络 投票相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2024 年 5 月 20 日 09 点 00 分 召开地点：漳州市芗城区漳州芗江酒店二楼芝山厅 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 20 日 至 2024 年 5 月 20 日 | 序 | 议案名称 | 投票股东类型 | | --- | --- | --- | | ...

Financial Performance - Revenue for 2023 reached 10,058,497,338.92 yuan, a 15.69% increase compared to 2022 [17] - Net profit attributable to shareholders was 2,797,351,515.70 yuan, up 13.15% year-on-year [17] - Total assets increased by 16.96% to 17,080,413,435.81 yuan at the end of 2023 [17] - Basic earnings per share (EPS) rose by 13.17% to 4.64 yuan [18] - Weighted average return on equity (ROE) decreased by 0.86 percentage points to 22.64% [18] - Operating cash flow decreased by 67.89% to 2,206,631,519.26 yuan due to changes in cash flow classification for fixed deposits [18] - Revenue for Q1 2023 was 262,951.76 million RMB, Q2 was 241,575.81 million RMB, Q3 was 255,460.11 million RMB, and Q4 was 245,862.05 million RMB [20] - Net profit attributable to shareholders in Q1 2023 was 76,968.13 million RMB, Q2 was 77,115.58 million RMB, Q3 was 86,381.14 million RMB, and Q4 was 39,270.30 million RMB [20] - Net cash flow from operating activities in Q1 2023 was 63,442.40 million RMB, Q2 was 73,418.57 million RMB, Q3 was 101,092.54 million RMB, and Q4 was -17,290.36 million RMB [20] - Non-recurring gains and losses for 2023 totaled -56,481,951.15 RMB, compared to -3,699,079.34 RMB in 2022 and 25,513,113.39 RMB in 2021 [23] - Government subsidies in 2023 amounted to 12,430,716.63 RMB, compared to 13,965,561.85 RMB in 2022 and 11,141,407.57 RMB in 2021 [22] - Total revenue for 2023 reached 10.06 billion yuan, a year-on-year increase of 15.69% [46] - Net profit for 2023 was 2.85 billion yuan, up 13.01% year-on-year [46] - Sales expenses increased by 61.95% to 782.78 million yuan, mainly due to increased promotion and advertising costs [47][49] - Other income surged by 97.72% to 21.52 million yuan, driven by VAT deduction policies [49] - Investment income rose by 67.78% to 126.19 million yuan, primarily due to increased interest income from time deposits [49] - The company's total assets stood at 17.08 billion yuan as of December 31, 2023 [46] - Operating cash flow decreased by 67.89% to 2.21 billion yuan, mainly due to changes in the classification of time deposits [49] - Total revenue for 2023 reached 1,003,618.59 million yuan, with a year-on-year increase of 15.70% [52][54] - The pharmaceutical manufacturing sector contributed 480,165.72 million yuan in revenue, a decrease of 75.77% compared to the previous year [52][54] - The pharmaceutical distribution sector generated 420,482.22 million yuan in revenue, with a year-on-year increase of 3.60% [52][54] - The cosmetics industry reported revenue of 70,675.80 million yuan, with a year-on-year increase of 62.18% [52][54] - Gross profit margin for the pharmaceutical distribution sector increased by 1.63 percentage points to 46.86% [52][54] - Online sales revenue was 73,000.11 million yuan, with a gross profit margin increase of 3.13 percentage points to 19.97% [55] - Offline sales revenue reached 930,618.48 million yuan, with a gross profit margin increase of 0.32 percentage points to 48.92% [55] - Production volume of liver disease drugs increased by 4.24% to 401.72 million boxes, while sales volume increased by 34.02% to 453.45 million boxes [56] - Direct material costs for liver disease drugs increased by 39.86% to 89,021.43 million yuan, accounting for 94.02% of total costs [57] - The total cost for pharmaceutical manufacturing increased by 43.30% to 116,353.40 million yuan, with direct material costs accounting for 92.76% [58] - Top 5 customers contributed sales of 883.46 million yuan, accounting for 8.80% of total annual sales [60] - Top 5 suppliers accounted for 1.21 billion yuan in procurement, representing 19.88% of total annual procurement [61] - Sales expenses increased by 61.95% to 782.78 million yuan, mainly due to increased promotion and advertising expenses [65] - Management expenses rose by 10.87% to 367.05 million yuan, primarily due to increased employee compensation and depreciation [66] - R&D investment totaled 232.35 million yuan, accounting for 2.31% of operating revenue [67] - The company has 237 R&D personnel, representing 8.50% of total employees [68] - Operating cash flow decreased by 4.67 billion yuan to 2.21 billion yuan, mainly due to changes in the classification of fixed deposits [71] - Investment cash flow improved by 3.53 billion yuan to -2.77 billion yuan, reflecting changes in fixed deposit classification [72] - Financing cash flow decreased by 193.48 million yuan to -769.30 million yuan, mainly due to reduced borrowing [72] - Cash and cash equivalents decreased by 53.58% to 11,587.46 million yuan, accounting for 6.78% of total assets [73] - Accounts receivable increased by 22.48% to 9,117.49 million yuan, accounting for 5.34% of total assets [73] - Inventory increased by 28.57% to 33,786.61 million yuan, accounting for 19.78% of total assets [73] - Other current assets increased by 45.56% to 91,442.74 million yuan, accounting for 53.54% of total assets [73] - Long-term equity investments decreased by 20.81% to 1,935.54 million yuan, accounting for 1.13% of total assets [73] - Construction in progress increased by 158.62% to 1,571.90 million yuan, accounting for 0.92% of total assets [73] - Retained earnings increased by 21.82% to 99,957.72 million yuan, accounting for 58.52% of total assets [74] - Overseas assets amounted to 518.35 million yuan, accounting for 0.30% of total assets [77] - Restricted assets totaled 1,071.76 million yuan, including 815.56 million yuan in cash and 256.19 million yuan in intangible assets [78] - The company's financial assets measured at fair value had a total impact of 21,720,121.28 RMB on current profits [25] - The company's financial assets measured at fair value totaled 4.91 billion yuan at the end of the period, with a net impact on other comprehensive income of 1.61 million yuan and a net impact on current profit of 21.72 million yuan [103] - The company's equity investments in listed companies, including Huarun Double-Crane, Liaoning Chengda, Industrial Securities, and Industrial Bank, had a total initial investment cost of 2.82 billion yuan and a total fair value of 3.66 billion yuan at the end of the period [104] - The total book value of private equity investments at the end of the period was RMB 1.2003 billion, with a net decrease of RMB 472.291 million during the period [105] - Xiamen Pien Tze Huang Hongren Pharmaceutical Co., Ltd. (consolidated) reported revenue of RMB 3.444 billion and net profit of RMB 1.1015 million [106] - Fujian Tongchun Pharmaceutical Co., Ltd. reported revenue of RMB 4.304 billion and net profit of RMB 53.6449 million [107] - The company distributed a cash dividend of 754,146,512.50 yuan (tax included) for 2022, accounting for 30.50% of the net profit attributable to shareholders [154] - The proposed cash dividend for 2023 is 1,399,695,927.20 yuan (tax included), representing 50.04% of the net profit attributable to shareholders [154][157] - The company did not propose any stock dividends or capital reserve to share capital conversion for 2023 [154][157] - The company's cash dividend policy ensures a minimum cash dividend ratio of not less than 30% of the distributable profit for the year, with adjustments requiring approval by two-thirds of the shareholders present at the general meeting [153] Research and Development - The company conducted 11 clinical studies on the secondary development of its core product, Pien Tze Huang, and completed 3 clinical studies [27] - The company completed 10 research projects on the pharmacological and toxicological effects of Pien Tze Huang, including its mechanism of action on bile acid metabolism and liver protection [27] - The company published 25 new research papers during the reporting period [27] - The company published a research paper on inhibiting colorectal cancer by regulating gut microbiota and metabolites in the top gastroenterology journal Gastroenterology (IF 29.4), enhancing product competitiveness [28] - 3 chemical drug Class 1 new drugs, 3 traditional Chinese medicine (TCM) Class 1.1 new drugs, and 1 TCM Class 1.2 new drug entered clinical research stage [28] - Obtained Phase II clinical trial summary report for Wandan Tablets, confirming clinical efficacy for mild to moderate generalized anxiety disorder [28] - Completed Phase I clinical research report for PZH2108 tablets, showing good safety and tolerability in Chinese healthy subjects [28] - Completed preclinical research for 2 chemical innovative drugs [28] - Newly authorized 26 invention patents and 4 utility model patents, transferred 2 invention patents [28] - Obtained 5 computer software copyright registration certificates and 2 non-major crop variety certification certificates [28] - 4 products including Compound Pien Tze Huang Ointment passed national patent-intensive product filing [28] - Passed the 2023 national intellectual property demonstration enterprise assessment and Fujian provincial intellectual property advantage enterprise review [28] - The company is focusing on secondary development of its core product Pien Tze Huang, as well as the development of new traditional Chinese medicine, classical formulas, and chemical drugs [85] - Key R&D projects include PZH2113 for tumors, PZH1215 for diabetic nephropathy, and PZH2114 for liver diseases, with various stages ranging from pre-clinical research to Phase II clinical trials [86] - The company has submitted applications for drug re-registration for Qinghuo Tablets and Sangju Ganmao Tablets, which are used for clearing heat and detoxifying, and treating wind-heat colds respectively [87] - R&D investment in 2023 was RMB 23,235.43 million, accounting for 2.31% of operating revenue [90] - The company's R&D investment accounted for 1.67% of net assets, with a capitalisation ratio of 0.00% [90] - The average R&D investment of peer companies was RMB 35,155.55 million [90] - Key R&D projects include modern disease spectrum research with an investment of RMB 7,691.41 million, a 17.88% increase year-on-year [92] - The company's R&D policy distinguishes between research and development phases, with development phase expenditures capitalised under specific conditions [88] Product Sales and Marketing - Sales of Pien Tze Huang capsules increased significantly during the reporting period, with Pien Tze Huang lozenges ranking first in sales in the liver and gallbladder medication category on Tmall and JD platforms [32] - Three major products, Angong Niuhuang Wan, Pien Tze Huang lozenges, and Ganbao, each achieved sales exceeding 100 million yuan [32] - The sales of Queen Brand Pien Tze Huang Pearl Cream exceeded 100 million yuan, and sales of five proprietary "Blue Hat" health food products doubled [32] - The company conducted over 4,500 offline terminal promotion activities and approximately 1,500 public welfare-themed activities, benefiting tens of thousands of people [33] - The company upgraded all "Pien Tze Huang Experience Halls" to "Pien Tze Huang Traditional Medicine Halls" starting January 3, 2024, to enhance brand image [45] - The company's terminal stores now cover over 100,000 locations through partnerships with major pharmacy chains [45] - The company's brand value was 40.94 billion yuan, ranking second among "China Time-Honored Brands" [43] - The company's sales model includes strategic partnerships with major pharmacy chains and the establishment of "Pien Tze Huang Traditional Medicine Halls" both domestically and internationally [93] - Business promotion expenses increased by 298.82 million yuan, with the parent company contributing an increase of 265.27 million yuan, Fujian Pien Tze Huang Cosmetics Co., Ltd. adding 40.24 million yuan, and Fujian Pien Tze Huang Health Food Co., Ltd. increasing by 13.49 million yuan, while Fujian Pien Tze Huang E-commerce Co., Ltd. decreased by 9.69 million yuan [98] - Advertising expenses decreased by 15.64 million yuan, with the parent company reducing expenses by 13.59 million yuan [99] - Operating expenses through e-commerce platforms decreased by 6.74 million yuan [99] - The company's sales expenses in 2023 were 783 million yuan, with a sales expense ratio of 7.78%, significantly lower than the industry average of 23.99 billion yuan and 44.33% [99] - Promotion, business promotion, and advertising expenses accounted for 67.90% of total sales expenses [94] - The company's main sales channels include domestic pharmacy sales, hospital sales, and overseas distribution [93] Corporate Governance and Leadership - The company held 2 shareholder meetings in the reporting period, addressing issues such as board reports, profit distribution, and financial budgets [118] - The company's board of directors held 7 meetings and 10 specialized committee meetings, with independent directors actively fulfilling their duties and providing professional opinions [119] - The company's board of directors revised the "Board Strategic Committee Work Rules" to enhance ESG governance and sustainability performance [119] - The company held two shareholders' meetings during the reporting period, with all proposals passed [123] - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period was 6.0237 million yuan [125] - The chairman of the board, Lin Zhihui, received a pre-tax remuneration of 234,800 yuan [124] - The general manager, Huang Jinming, received a pre-tax remuneration of 563,500 yuan [124] - The total pre-tax remuneration for independent directors during the reporting period was 240,000 yuan [124] - The total pre-tax remuneration for supervisors during the reporting period was 1.8012 million yuan [124] - The total pre-tax remuneration for senior management during the reporting period was 2.0237 million yuan [125] - The company's financial report for 2022 and financial budget for 2023 were approved at the 2022 annual shareholders' meeting [123] - The company's profit distribution plan for 2022 was approved at the 2022 annual shareholders' meeting [123] - The company's proposal to appoint additional directors was approved at the 2023 first extraordinary shareholders' meeting [123] - Lin Zhihui was appointed as the company's Party Committee Secretary and Chairman in August 2023 [126] - Huang Jinming has been serving as the company's Deputy Party Committee Secretary, Director, and General Manager since July 2019 [126] - Lai Wenning has been serving as the company's Director since December 2022 [126] - Yang Haipeng has been serving as the company's Director and Chief Accountant since January 2022 [126] - Fan Zhipeng has been serving as the company's Independent Director since March 2018 [126] - Du Shouying, born in December 1960, holds a Ph.D. in Clinical Chinese Medicine from Beijing University of Chinese Medicine and serves as an independent director for Hunan Fangsheng Pharmaceutical Co., Ltd. and Chongqing Huasen Pharmaceutical Co., Ltd. [127] - Zhang Lei, born in October 1985, is a Certified Public Accountant and currently serves as the director of the Shenzhen branch of Tianzhi International Accounting Firm (Special General Partnership). [127] - Chen Lei, born in January 1981, holds a Ph.D. in Finance and is currently a professor and vice dean at the School of Finance and Economics, Jimei University, and also serves as an independent director for Ruida Fund Management Co., Ltd. [127] - Xu Shibin, born in May 1972, has extensive experience in government and corporate roles, currently serving as the Deputy Party Secretary and Chairman of the Supervisory Board of the company. [127] - Huang Yalong, born in December 1965, is a senior accountant with a long history in the company's financial department, currently serving as the Director of the Audit Department and a staff supervisor. [127] - Wei Tengyun, born in February 1972, is a licensed pharmacist and engineer, currently serving as the Director of the First Workshop and a staff supervisor at the company. [127] - Chen Yuhong has been serving as the company's supervisor and director of the Enterprise Management Department since June 2022 [128] - Huang Qiumin has been serving as the company's supervisor and director of the Securities Investment Department since June 2022, and also as the chairman of Zhangzhou Pien Tze Huang Investment Management Co., Ltd [128] - Hong Fei has been serving as the company's vice president since August 2022 [128] - Chen Honghui has been serving as the company's vice president and board secretary since August 2022 [128] - Zhang Zexiu has been serving as the company's vice president and chairman of Fujian Pien Tze Huang Health Food Co., Ltd since January 2024 [128] - Lai Wenning has been serving as a director and vice president of Zhangzhou Jiulongjiang Group Co., Ltd since April 2022 [129] - Fan Zhipeng serves as a partner at Beijing Danggui Yuanz

漳州片仔癀药业股份有限公司 2023 年度独立董事述职报告（范志鹏） 2023 年度，本人作为漳州片仔癀药业股份有限公司（以 下简称"公司"）第七届董事会独立董事，严格遵照《中华 人民共和国公司法》《中华人民共和国证券法》《中国证监会 上市公司治理准则》《中国证监会上市公司独立董事规则》 等法律法规，以及《漳州片仔癀药业股份有限公司章程》（以 下简称"《公司章程》"）、《漳州片仔癀药业股份有限公司独 立董事工作制度》等规范性要求，诚信、勤勉、尽责、忠实 履行职务，积极出席 2023 年度的相关会议，认真审议董事 会各项议案，充分发挥了独立董事及各专业委员会委员的作 用，切实维护公司和股东尤其是中小股东的合法权益。现将 本人 2023 年度履职情况报告如下： 一、独立董事的基本情况 作为公司独立董事，本人拥有较丰富的法学专业知识和 经验，具备国际法专业硕士学位，通过律师资格考试（现为 "国家统一司法考试"），在从事的专业领域积累了丰富的经 验。本人个人工作履历、专业背景以及任职情况如下： 范志鹏，男，1976 年 6 月出生，南京大学法学硕士。现 为北京当归远志文化发展有限公司合伙人，上海小多金融服 务有限责任 ...

证券代码：600436 证券简称：片仔癀 公告编号：2024-021 漳州片仔癀药业股份有限公司 2024年第一季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第3号——行业信息披 露》（2022年修订）《上市公司行业信息披露指引第六号——医药制造》 （2022年修订）等相关法律法规，漳州片仔癀药业股份有限公司（以下 简称"公司"）现将2024年第一季度主要经营数据披露如下： 一、 公司 2024 年第一季度主营业务分行业情况 单位：万元 人民币 | 行业 | 主营业务 | 主营业务 | 毛利率 | 主营业务 收入增长 | 主营业务 成本增长 | 毛利率 | | --- | --- | --- | --- | --- | --- | --- | | | 收入 | 成本 | （%） | 率（%） | 率（%） | 增减情况 | | 医药 | 165,374.40 | 48,820.37 | 70.48 | 25.94 | 57.03 | 减少5.84个 | | 制造业 ...

漳州片仔癀药业股份有限公司 2023 年度董事会工作报告 各位董事、监事、高级管理人员： 大家好，现在我代表公司董事会，向各位汇报董事会 2023 年度工作情况和 2024 年度工作计划，请予以审议。 2023 年是全面贯彻落实党的二十大精神的开局之年，也是 "十四五"规划承上启下的关键之年。公司董事会坚持以习近 平新时代中国特色社会主义思想为指导，深入贯彻落实党的二 十大精神，在各位股东的有力支持下，围绕"守正创新、行稳 致远"发展理念，踔厉奋发，团结协作，带领全体干部员工齐 心协力，认真完成各项工作，有力推动片仔癀高质量发展。 一、 经营发展成果 （一）经营业绩再创新高：2023 年公司实现合并营业收入 1,005,849.73 万元，比增 15.69%；实现利润总额 336,891.25 万元，比增 13.14%；实现归母净利润 279,735.15 万元，比增 13.15%；实现上缴税收 119,186.72 万元；完成全年经营目标。 （二）企业荣誉硕果累累：公司被国务院国资委纳入"双 百企业"名单；入选国务院国资委"创建世界一流专业领军示 范企业"名单，为中药领域唯一获此殊荣的企业；上榜"中药 上市 ...